4519.T | Ticker Profile - Titan Protect

4519.T

Chugai Pharmaceutical

Health Care · Pharmaceuticals · TSE

$7,465.00

Data: 2026-05-09

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$13.0T

Total market value of the company

Trailing P/E

29.94

Premium valuation

Forward P/E

33.49

Based on estimated future earnings — lower means cheaper

Rev Growth

+11.5%

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

23.7%

Return on equity — how efficiently it uses shareholder money

Analyst Target

N/A

Recommendation

N/A

Consensus view from ? analysts covering this stock

About Chugai Pharmaceutical

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept, an immunosuppressant; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi, a spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody.

Country: Japan Industry: Drug Manufacturers - General

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

17.3% PASS

Interest-bearing cash below 33% of assets

Receivables

17.9% PASS

Receivables below 49% of assets

Revenue Purity

0.1% PASS

Non-compliant revenue below 5% — any excess requires purification

Valuation

Fair Value Est.

$3,127.52

What our model estimates this business is worth per share

Margin of Safety

-138.7%

Trading above fair value — no margin of safety

Rating

AVOID

Overall assessment combining ethics, valuation, and quality

Percentile

71.3th

Ranks in the top 29% of our 13,571 screened universe

Ethical Score

76.3

Valuation Score

30.5

Quality Score

54.0

Combined

N/A

Trading at $7900, 153% above fair value of $3128. Passes all ethical screens. Ranks better than 50% of screened stocks.

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

0.816

Good returns relative to risk taken

Kelly Fraction

0.0691

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

1.028

Returns exceed worst-case losses — strong risk profile

Annual Return

29.9%

Historical annualised return based on price data

Max Drawdown

-29.1%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$N/A

52W Low

$N/A

Avg Volume

N/A

Average daily shares traded — higher means easier to buy and sell

Short Ratio

N/A

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

1.7%

Annual dividend as a percentage of the share price

EPS (TTM)

$263.86

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

49.4%

Profit from core operations before interest and tax

Free Cash Flow

N/A

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

N/A

Loss-making — spending exceeds revenue after all costs

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-09

Before you go